Cianna gets $9m in debut financing round
This article was originally published in Clinica
Executive Summary
Aliso Viejo, California-based Cianna Medical has closed a $9m series A funding to expand commercialisation of its Savi breast brachytherapy applicator. Participants in the financing were Fog City Fund and Windamere Venture Partners - both were initial investors in BioLucent from which Cianni was spun out - and several private individuals. Cianni was created when BioLucent was acquired by Hologic in June 2007. Its Savi device is designed to deliver more targeted radiation therapy within the breast, thereby reducing the treatment time from 6-7 weeks to five days.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.